Find information on medical topics, symptoms, drugs, procedures, news and more, written for the health care professional.

* This is a professional Version *

Acute Kidney Injury (AKI)

(Acute Renal Failure)

by James I. McMillan, MD

Acute kidney injury is a rapid decrease in renal function over days to weeks, causing an accumulation of nitrogenous products in the blood (azotemia). It often results from severe trauma, illness, or surgery but is sometimes caused by a rapidly progressive, intrinsic renal disease. Symptoms include anorexia, nausea, and vomiting. Seizures and coma may occur if the condition is untreated. Fluid, electrolyte, and acid-base disorders develop quickly. Diagnosis is based on laboratory tests of renal function, including serum creatinine. Urinary indices, urinary sediment examination, and often imaging and other tests are needed to determine the cause. Treatment is directed at the cause but also includes fluid and electrolyte management and sometimes dialysis.

In all cases of acute kidney injury (AKI), creatinine and urea build up in the blood over several days, and fluid and electrolyte disorders develop. The most serious of these disorders are hyperkalemia and fluid overload (possibly causing pulmonary edema). Phosphate retention leads to hyperphosphatemia. Hypocalcemia is thought to occur because the impaired kidney no longer produces calcitriol and because hyperphosphatemia causes Ca phosphate precipitation in the tissues. Acidosis develops because hydrogen ions cannot be excreted. With significant uremia, coagulation may be impaired, and pericarditis may develop. Urine output varies with the type and cause of AKI.

Etiology

Causes of AKI (see Major Causes of Acute Kidney Injury) can be classified as

  • Prerenal

  • Renal

  • Postrenal

Prerenal azotemia is due to inadequate renal perfusion. The main causes are ECF volume depletion and cardiovascular disease. Prerenal conditions cause about 50 to 80% of AKI but do not cause permanent kidney damage (and hence are potentially reversible) unless hypoperfusion is severe enough to cause tubular ischemia. Hypoperfusion of an otherwise functioning kidney leads to enhanced reabsorption of Na and water, resulting in oliguria with high urine osmolality and low urine Na.

Renal causes of AKI involve intrinsic kidney disease or damage. Renal causes are responsible for about 10 to 40% of cases. Overall, the most common causes are prolonged renal ischemia and nephrotoxins (including IV use of iodinated radiopaque contrast agents—see Contrast Nephropathy). Disorders may involve the glomeruli, tubules, or interstitium. Glomerular disease reduces GFR and increases glomerular capillary permeability to proteins; it may be inflammatory (glomerulonephritis) or the result of vascular damage from ischemia or vasculitis. Tubules also may be damaged by ischemia and may become obstructed by cellular debris, protein or crystal deposition, and cellular or interstitial edema. Tubular damage impairs reabsorption of Na, so urinary Na tends to be elevated, which is helpful diagnostically. Interstitial inflammation (nephritis) usually involves an immunologic or allergic phenomenon. These mechanisms of tubular damage are complex and interdependent, rendering the previously popular term acute tubular necrosis an inadequate description.

Postrenal azotemia (obstructive nephropathy—see also Obstructive Uropathy) is due to various types of obstruction in the voiding and collecting parts of the urinary system and is responsible for about 5 to 10% of cases. Obstruction can also occur within the tubules when crystalline or proteinaceous material precipitates. This form of renal failure is often grouped with postrenal failure because the mechanism is obstructive. Obstructed ultrafiltrate flow in tubules or more distally increases pressure in the urinary space of the glomerulus, reducing GFR. Obstruction also affects renal blood flow, initially increasing the flow and pressure in the glomerular capillary by reducing afferent arteriolar resistance. However, within 3 to 4 h, the renal blood flow is reduced, and by 24 h, it has fallen to < 50% of normal because of increased resistance of renal vasculature. Renovascular resistance may take up to a week to return to normal after relief of a 24-h obstruction. To produce significant azotemia, obstruction at the level of the ureter requires involvement of both ureters unless the patient has only a single functioning kidney. Bladder outlet obstruction is probably the most common cause of sudden, and often total, cessation of urinary output in men.

Urine output

Prerenal causes typically manifest with oliguria, not anuria. Anuria usually occurs only in obstructive uropathy or, less commonly, in bilateral renal artery occlusion, acute cortical necrosis, or rapidly progressive glomerulonephritis.

A relatively preserved urine output of 1 to 2.4 L/day is initially present in most renal causes. In acute tubular injury, output may have 3 phases.

  • The prodromal phase, with usually normal urine output, varies in duration depending on causative factors (eg, the amount of toxin ingested, the duration and severity of hypotension).

  • The oliguric phase, with output typically between 50 and 400 mL/day, lasts an average of 10 to 14 days but varies from 1 day to 8 wk. However, many patients are never oliguric. Nonoliguric patients have lower mortality and morbidity and less need for dialysis.

  • In the postoliguric phase, urine output gradually returns to normal, but serum creatinine and urea levels may not fall for several more days. Tubular dysfunction may persist and is manifested by Na wasting, polyuria (possibly massive) unresponsive to vasopressin , or hyperchloremic metabolic acidosis.

Major Causes of Acute Kidney Injury

Cause

Examples

Prerenal

ECF volume depletion

Excessive diuresis, hemorrhage, GI losses, loss of intravascular fluid into the extravascular space (due to ascites, peritonitis, pancreatitis, or burns), loss of skin and mucus membranes, renal salt- and water-wasting states

Low cardiac output

Cardiomyopathy, MI, cardiac tamponade, pulmonary embolism, pulmonary hypertension, positive-pressure mechanical ventilation

Low systemic vascular resistance

Septic shock, liver failure, antihypertensive drugs

Increased renal vascular resistance

NSAIDs, cyclosporine, tacrolimus, hypercalcemia, anaphylaxis, some anesthetics, renal artery obstruction, renal vein thrombosis, sepsis, hepatorenal syndrome

Decreased efferent arteriolar tone (leading to decreased GFR from reduced glomerular transcapillary pressure, especially in patients with bilateral renal artery stenosis)

ACE inhibitors or angiotensin II receptor blockers

Renal

Acute tubular injury

Ischemia (prolonged or severe prerenal state): Surgery, hemorrhage, arterial or venous obstruction, NSAIDs, cyclosporine, tacrolimus, amphotericin B

Toxins: Aminoglycosides, amphotericin B, foscarnet, ethylene glycol, hemoglobin (as in hemoglobinuria), myoglobin (as in myoglobinuria), ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, streptozotocin

Acute glomerulonephritis

ANCA-associated: Crescentic glomerulonephritis, polyarteritis nodosa, granulomatosis with polyangiitis (formerly Wegener granulomatosis)

Anti-GBM glomerulonephritis: Goodpasture syndrome

Immune-complex: Lupus glomerulonephritis, postinfectious glomerulonephritis, cryoglobulinemic glomerulonephritis

Acute tubulointerstitial nephritis

Drug reaction (eg, β-lactams, NSAIDs, sulfonamides, ciprofloxacin, thiazide diuretics, furosemide, cimetidine, phenytoin, allopurinol), pyelonephritis, papillary necrosis

Acute vascular nephropathy

Vasculitis, malignant hypertension, thrombotic microangiopathies, systemic sclerosis, atheroembolism

Infiltrative diseases

Lymphoma, sarcoidosis, leukemia

Postrenal

Tubular precipitation

Uric acid (tumor lysis), sulfonamides, triamterene, acyclovir, indinavir, methotrexate, Ca oxalate (ethylene glycol ingestion), myeloma protein, myoglobin

Ureteral obstruction

Intrinsic: Calculi, clots, sloughed renal tissue, fungus ball, edema, cancer, congenital defects

Extrinsic: Cancer, retroperitoneal fibrosis, ureteral trauma during surgery or high impact injury

Bladder obstruction

Mechanical: Benign prostatic hyperplasia, prostate cancer, bladder cancer, urethral strictures, phimosis, paraphimosis, urethral valves, obstructed indwelling urinary catheter

Neurogenic: Anticholinergic drugs, upper or lower motor neuron lesion

ANCA = antineutrophil cytoplasmic antibody; GBM = glomerular basement membrane.


Symptoms and Signs

Initially, weight gain and peripheral edema may be the only findings. Often, predominant symptoms are those of the underlying illness or those caused by the surgical complication that precipitated renal deterioration. Later, as nitrogenous products accumulate, symptoms of uremia may develop, including anorexia, nausea, vomiting, weakness, myoclonic jerks, seizures, confusion, and coma; asterixis and hyperreflexia may be present on examination. Chest pain (typically worse with inspiration or when recumbent), a pericardial friction rub, and findings of pericardial tamponade may occur if uremic pericarditis is present. Fluid accumulation in the lungs may cause dyspnea and crackles on auscultation.

Other findings depend on the cause. Urine may be cola-colored in glomerulonephritis or myoglobinuria. A palpable bladder may be present with outlet obstruction. The costovertebral angle may be tender if the kidney is acutely enlarged.

Diagnosis

  • Serum creatinine

  • Urinary sediment

  • Urinary diagnostic indices

  • Postvoid residual bladder volume if postrenal cause suspected

AKI is suspected when urine output falls or serum BUN and creatinine rise. Evaluation should determine the presence and type of AKI and seek a cause. Blood tests generally include CBC, BUN, creatinine, and electrolytes (including Ca and phosphate). Urine tests include Na and creatinine concentration and microscopic analysis of sediment. Early detection and treatment increase the chances of reversing renal failure and in some cases preventing it.

A progressive daily rise in serum creatinine is diagnostic of AKI. Serum creatinine can increase by as much as 2 mg/dL/day (180 μmol/L/day), depending on the amount of creatinine produced (which varies with lean body mass) and total body water. A rise of > 2 mg/dL/day suggests overproduction due to rhabdomyolysis.

Urea nitrogen may increase by 10 to 20 mg/dL/day (3.6 to 7.1 mmol urea/L/day), but BUN may be misleading because it is frequently elevated in response to increased protein catabolism resulting from surgery, trauma, corticosteroids, burns, transfusion reactions, parenteral nutrition or GI or internal bleeding.

When creatinine is rising, 24-h urine collection for creatinine clearance and the various formulas used to calculate creatinine clearance from serum creatinine are inaccurate and should not be used in estimating GFR, because the rise in serum creatinine concentration is a delayed function of GFR decline.

Other laboratory findings are progressive acidosis, hyperkalemia, hyponatremia, and anemia. Acidosis is ordinarily moderate, with a plasma HCO 3 content of 15 to 20 mmol/L. Serum K concentration increases slowly, but when catabolism is markedly accelerated, it may rise by 1 to 2 mmol/L/day. Hyponatremia usually is moderate (serum Na, 125 to 135 mmol/L) and correlates with a surplus of water. Normochromic-normocytic anemia with an Hct of 25 to 30% is typical.

Hypocalcemia is common and may be profound in patients with myoglobinuric AKI, apparently because of the combined effects of Ca deposition in necrotic muscle, reduced calcitriol production, resistance of bone to parathyroid hormone (PTH), and hyperphosphatemia. During recovery from AKI, hypercalcemia may supervene as renal calcitriol production increases, the bone becomes responsive to PTH, and Ca deposits are mobilized from damaged tissue.

Determination of cause

Immediately reversible prerenal or postrenal causes must be excluded first. ECF volume depletion and obstruction are considered in all patients. The drug history must be accurately reviewed and all potentially renal toxic drugs stopped. Urinary diagnostic indices (see Urinary Diagnostic Indices in Prerenal Azotemia and Acute Tubular Injury) are helpful in distinguishing prerenal azotemia from acute tubular injury, which are the most common causes of AKI in hospitalized patients.

Prerenal causes are often apparent clinically. If so, correction of an underlying hemodynamic abnormality should be attempted. For example, in hypovolemia, volume infusion can be tried, in heart failure, diuretics and afterload reducing drugs can be tried, and in liver failure, octreotide can be tried. Abatement of AKI confirms a prerenal cause.

Urinary Diagnostic Indices in Prerenal Azotemia and Acute Tubular Injury

Index

Prerenal

Tubular Injury

U/P osmolality

> 1.5

1–1.5

Urine Na (mmol/L)

< 10

> 40

Fractional excretion of Na (FE Na )*

< 1%

> 1%

Renal failure index

< 1

> 2

BUN/creatinine ratio

> 20

< 10

*U/P Na ÷ U/P creatinine.

Urine Na ÷ U/P creatinine ratio.

AGN = acute glomerulonephritis; U/P = urine-to-plasma ratio.

Adapted from Miller TR, Anderson RJ, Linas SL, et al: Urinary diagnostic indices in acute renal failure. Annals of Internal Medicine 89(1):47–50, 1978; used with permission of the American College of Physicians and the author.

Postrenal causes should be sought in most cases of AKI. Immediately after the patient voids, bedside ultrasonography of the bladder is done (or, alternatively, a urinary catheter is placed) to determine the residual urine in the bladder. A postvoid residual urine volume > 200 mL suggests bladder outlet obstruction, although detrusor muscle weakness and neurogenic bladder may also cause residual volume of this amount. The catheter may be kept in for the first day to monitor hourly output but is removed once oliguria is confirmed (if bladder outlet obstruction is not present) to decrease risk of infection. Renal ultrasonography is then done to diagnose more proximal obstruction. However, sensitivity for obstruction is only 80 to 85% when ultrasonography is used because the collecting system is not always dilated, especially when the condition is acute, an intrarenal pelvis is present, the ureter is encased (eg, in retroperitoneal fibrosis or neoplasm), or the patient has concomitant hypovolemia. If obstruction is strongly suspected, noncontrast CT can establish the site of obstruction and guide therapy.

The urinary sediment may provide etiologic clues. A normal urine sediment occurs in prerenal azotemia and sometimes in obstructive uropathy. With renal tubular injury, the sediment characteristically contains tubular cells, tubular cell casts, and many granular casts (often with brown pigmentation). Urinary eosinophils suggest allergic tubulointerstitial nephritis. RBC casts indicate glomerulonephritis or vasculitis.

Renal causes are sometimes suggested by clinical findings. Patients with glomerulonephritis (see Glomerular Disorders) often have edema, marked proteinuria (nephrotic syndrome), or signs of arteritis in the skin and retina, often without a history of intrinsic renal disease. Hemoptysis suggests granulomatosis with polyangiitis (formerly Wegener granulomatosis) or Goodpasture syndrome. Certain rashes (eg, erythema nodosum, cutaneous vasculitis, discoid lupus) suggest polyarteritis, cryoglobulinemia, SLE, or Henoch-Schönlein purpura. Tubulointerstitial nephritis and drug allergy are suggested by a history of drug ingestion and a maculopapular or purpuric rash.

To further differentiate renal causes, antistreptolysin-O and complement titers, antinuclear antibodies, and antineutrophil cytoplasmic antibodies are determined. Renal biopsy may be done if the diagnosis remains elusive (see Causes of Acute Kidney Injury Based on Laboratory Findings).

Causes of Acute Kidney Injury Based on Laboratory Findings

Blood Test

Finding

Possible Diagnosis

Antiglomerular basement membrane antibodies

Positive

Goodpasture syndrome

Antineutrophil cytoplasmic antibodies

Positive

Small-vessel vasculitis (granulomatosis with polyangiitis [formerly Wegener granulomatosis] or polyarteritis nodosa)

Antinuclear antibodies or antibodies to double-stranded DNA

Positive

SLE

Antistreptolysin-O or antibodies to streptokinase or hyaluronidase

Positive

Poststreptococcal glomerulonephritis

CK or myoglobin level

Markedly elevated

Rhabdomyolysis

Complement titers

Low

Postinfectious glomerulonephritis, SLE, subacute bacterial endocarditis, cholesterol embolization

Protein electrophoresis (serum)

Monoclonal spike

Multiple myeloma

Uric acid level

Elevated

Cancer or tumor lysis syndrome (leading to uric acid crystals)

Prerenal acute renal failure


Imaging

In addition to renal ultrasonography, other imaging tests are occasionally of use. In evaluating for ureteral obstruction, noncontrast CT is preferred over antegrade and retrograde urography. In addition to its ability to delineate soft-tissue structures and Ca-containing calculi, CT can detect nonradiopaque calculi.

Contrast agents should be avoided if possible. However, renal arteriography or venography may sometimes be indicated if vascular causes are suggested clinically. Magnetic resonance angiography was increasingly being used for diagnosing renal artery stenosis as well as thrombosis of both arteries and veins because MRI used gadolinium, which was thought to be safer than the iodinated contrast agents used in angiography and contrast-enhanced CT. However, recent evidence suggests that gadolinium may be involved in the pathogenesis of nephrogenic systemic fibrosis, a serious complication that occurs only in patients with AKI. Thus, gadolinium should be avoided if possible in patients with renal failure.

Kidney size, as determined with imaging tests, is helpful to know, because a normal or enlarged kidney favors reversibility, whereas a small kidney suggests chronic renal insufficiency.


Prognosis

Although many causes are reversible if diagnosed and treated early, the overall survival rate remains about 50% because many patients with AKI have significant underlying disorders (eg, sepsis, respiratory failure). Death is usually the result of these disorders rather than AKI itself. Most survivors have adequate kidney function. About 10% require dialysis or transplantation—half right away and the others as renal function slowly deteriorates.

Treatment

  • Immediate treatment of pulmonary edema and hyperkalemia

  • Dialysis as needed to control hyperkalemia, pulmonary edema, metabolic acidosis, and uremic symptoms

  • Adjustment of drug regimen

  • Usually restriction of water, Na, phosphate, and K intake, but provision of adequate protein

  • Possibly phosphate binders and Na polystyrene sulfonate

Emergency treatment

Life-threatening complications are addressed, preferably in a critical care unit. Pulmonary edema (see Pulmonary Edema) is treated with O 2 , IV vasodilators (eg, nitroglycerin), and diuretics (often ineffective in AKI). Hyperkalemia (see Hyperkalemia) is treated as needed with IV infusion of 10 mL of 10% Ca gluconate, 50 g of dextrose, and 5 to 10 units of insulin. These drugs do not reduce total body K, so further (but slower acting) treatment with 30 g of oral or rectal Na polystyrene sulfonate is begun. Although correction of an anion gap metabolic acidosis with NaHCO 3 is controversial, correction of the nonanion gap portion of severe metabolic acidosis (pH < 7.20) is less controversial. The nonanion gap portion may be treated with IV NaHCO 3 in the form of a slow infusion ( 150 mEq NaHCO 3 in 1 L of 5% D/W at a rate of 50 to 100 mL/h). The nonanion gap portion of metabolic acidosis is determined by calculating the increase in anion gap above normal and then subtracting this number from the decrease in HCO 3 from 24 mmol/L. HCO 3 is given to raise the serum HCO 3 by this difference. Because variations in body buffer systems and the rate of acid production are hard to predict, calculating the amount of HCO 3 needed to achieve a full correction is usually not recommended. Instead, HCO 3 is given via continuous infusion and the anion gap is monitored serially.

Hemodialysis (see Hemodialysis) or hemofiltration (see Continuous Hemofiltration and Hemodialysis) is initiated when

  • Severe electrolyte abnormalities cannot otherwise be controlled (eg, K > 6 mmol/L)

  • Pulmonary edema persists despite drug treatment

  • Metabolic acidosis is unresponsive to treatment

  • Uremic symptoms occur (eg, vomiting thought to be due to uremia, asterixis, encephalopathy, pericarditis, seizures)

BUN and creatinine levels are probably not the best guides for initiating dialysis in AKI. In asymptomatic patients who are not seriously ill, particularly those in whom return of renal function is considered likely, dialysis can be deferred until symptoms occur, thus avoiding placement of a central venous catheter with its attendant complications.


General measures

Nephrotoxic drugs are stopped, and all drugs excreted by the kidneys (eg, digoxin, some antibiotics) are adjusted; serum levels are useful.

Daily water intake is restricted to a volume equal to the previous day’s urine output plus measured extrarenal losses (eg, vomitus) plus 500 to 1000 mL/day for insensible loss. Water intake can be further restricted for hyponatremia or increased for hypernatremia. Although weight gain indicates excess fluid, water intake is not decreased if serum Na remains normal; instead, dietary Na is restricted.

Na and K intake is minimized except in patients with prior deficiencies or GI losses. An adequate diet should be provided, including daily protein intake of about 0.8 g/kg. If oral or enteral nutrition is impossible, parenteral nutrition is used; however, in AKI, risks of fluid overload, hyperosmolality, and infection are increased by IV nutrition. Ca salts (carbonate, acetate) or synthetic non–Ca-containing phosphate binders before meals help maintain serum phosphate at < 5 mg/dL (< 1.78 mmol/L). If needed to help maintain serum K at < 6 mmol/L in the absence of dialysis (eg, if other therapies, such as diuretics, fail to lower K), a cation-exchange resin, Na polystyrene sulfonate, is given 15 to 60 g po or rectally 1 to 4 times/day as a suspension in water or in a syrup (eg, 70% sorbitol). An indwelling bladder catheter is rarely needed and should be used only when necessary because of an increased risk of UTI and urosepsis.

In many patients, a brisk and even dramatic diuresis after relief of obstruction is a physiologic response to the expansion of ECF during obstruction and does not compromise volume status. However, polyuria accompanied by the excretion of large amounts of Na, K, Mg, and other solutes may cause hypokalemia, hyponatremia, hypernatremia (if free water is not provided), hypomagnesemia, or marked contraction of ECF volume with peripheral vascular collapse. In this postoliguric phase, close attention to fluid and electrolyte balance is mandatory. Overzealous administration of salt and water after relief of obstruction can prolong diuresis. When postoliguric diuresis occurs, replacement of urine output with 0.45% saline at about 75% of urine output prevents volume depletion and the tendency for excessive free water loss while allowing the body to eliminate excessive volume if this is the cause of the polyuria.


Prevention

AKI can often be prevented by maintaining normal fluid balance, blood volume, and BP in patients with trauma, burns, or severe hemorrhage and in those undergoing major surgery. Infusion of isotonic saline and blood may be helpful. Use of contrast agents should be minimized, particularly in at-risk groups (eg, the elderly and those with preexisting renal insufficiency, volume depletion, diabetes, or heart failure). If contrast agents are necessary, risk can be lowered by minimizing volume of the IV contrast agent, using nonionic and low osmolal or iso-osmolal contrast agents, avoiding NSAIDs, and pretreating with normal saline at 1 mL/kg/h IV for 12 h before the test. Pre- and post-contrast infusion of isotonic NaHCO 3 has also been used successfully instead of normal saline. N -acetylcysteine 600 mg po bid the day before and the day of IV contrast administration has been used to prevent contrast nephropathy, but reports of its efficacy are conflicting.

Before cytolytic therapy is initiated in patients with certain neoplastic diseases (eg, lymphoma, leukemia), treatment with rasburicase or allopurinol should be considered along with increasing urine flow by increasing oral or IV fluids to reduce urate crystalluria. Making the urine more alkaline (by giving oral or IV NaHCO 3 or acetazolamide) has been recommended by some but is controversial because it may also induce urinary Ca phosphate precipitation and crystalluria, which may worsen AKI.

The renal vasculature is very sensitive to endothelin, a potent vasoconstrictor that reduces renal blood flow and GFR. Endothelin is implicated in progressive renal damage, and endothelin receptor antagonists have successfully slowed or even halted experimental renal disease. Antiendothelin antibodies and endothelin-receptor antagonists are being studied to protect the kidney against ischemic AKI.

Key Points

  • Causes of AKI can be prerenal (eg, kidney hypoperfusion), renal (eg, direct effects on the kidney), or postrenal (eg, urinary tract obstruction distal to the kidneys).

  • With AKI, consider ECF volume depletion and nephrotoxins, obtain urinary diagnostic indices and measure bladder residual volume to identify obstruction.

  • Avoid using IV contrast in imaging studies.

  • Initiate hemodialysis or hemofiltration as needed for pulmonary edema, hyperkalemia, metabolic acidosis, or uremic symptoms unresponsive to other treatments.

  • Minimize risk of AKI in patients at risk by maintaining normal fluid balance, avoiding nephrotoxins (including contrast agents) when possible, and taking precautions such as giving fluids or drugs when contrast or cytolytic therapy is necessary.

Resources In This Article

Drugs Mentioned In This Article

  • Drug Name
    Select Trade
  • ROCALTROL
  • DYRENIUM
  • LASIX
  • ZOVIRAX
  • PROGRAF
  • IFEX
  • NEORAL, SANDIMMUNE
  • CILOXAN, CIPRO
  • CRIXIVAN
  • FOSCAVIR
  • ZYLOPRIM
  • TAGAMET
  • OTREXUP
  • DILANTIN
  • VASOSTRICT
  • SANDOSTATIN
  • NITRO-DUR
  • LANOXIN
  • DIAMOX
  • ELITEK
  • ACETADOTE

* This is a professional Version *